7.12.2023 16:12:32 CET | ViroGates | Managers' transactions

COMPANY ANNOUNCEMENT - No. 21-2023 - 7th December 2023

MAY NOT BE PUBLISHED, DISTRIBUTED OR DELIVERED FULLY OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, UNITED KINGDOM, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

Under the EU’s Market Abuse Regulation article 19, ViroGates A/S must notify Finanstilsynet and publicly disclose transactions made by persons discharging managerial responsibilities and persons closely associated with them on the trading of ViroGates shares. 

ViroGates hereby notifies and submits the following transaction of shares in ViroGates:

Jakob Knudsen, Chief executive officer of ViroGates A/S, bought subscription rights to shares in ViroGates on 5^th and 6^th December 2023. The subscription rights are related to the ongoing Rights emission in ViroGates.

The Form related to the transaction is attached.

The announcement can be found at https://www.virogates.com/announcements/.

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: ca@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff. The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

• Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

Attachments

• 20231207 -ViroGates Company ann. 21.pdf
• 20231207 FT indberetning ledende medarbejder.pdf